Elicio (ELTX) Director Nissenson Receives 21,750-Share Award

What Happened Allen Nissenson, a non-employee director of Elicio Therapeutics, was granted a 21,750-share derivative equity award on 2026-08-31. The filing reports the grant at $0.00 (derivative instrument), meaning no cash was paid at grant; the award is subject to future vesting and exercisability conditions.

Key Details

• Transaction date: August 31, 2026; Form 4 filed September 2, 2026 (timely filing).
• Instrument: Derivative award (reported as an acquisition/award, code A) for 21,750 shares at $0.00.
• Vesting: Award vests and becomes exercisable in full on the earlier of (A) August 31, 2027 or (B) the Issuer’s 2027 annual meeting, provided the director continues service through vesting.
• Shares owned after the transaction: Not specified in the filing.
• Footnote: The grant is the director’s annual non-employee director equity award; no additional award will be made to the reporting person in connection with the 2026 annual meeting.

Context This is an equity award (derivative grant) to a non-employee director rather than a market purchase or sale. Such grants are routine compensation for board service and vest over time; they do not by themselves indicate buying or selling of outstanding shares until exercised or sold.